van Megen H - Search Results

1

The panicogenic effects of cholecystokinin-tetrapeptide are antagonized by L-365,260, a central cholecystokinin receptor antagonist, in patients with panic disorder.

Bradwejn J, Koszycki D, Couëtoux du Tertre A, van Megen H, den Boer J, Westenberg H. Bradwejn J, et al. Among authors: van megen h. Arch Gen Psychiatry. 1994 Jun;51(6):486-93. doi: 10.1001/archpsyc.1994.03950060050005. Arch Gen Psychiatry. 1994. PMID: 8192551 Clinical Trial.

2

Pentagastrin induced panic attacks: enhanced sensitivity in panic disorder patients.

van Megen HJ, Westenberg HG, den Boer JA, Haigh JR, Traub M. van Megen HJ, et al. Psychopharmacology (Berl). 1994 Apr;114(3):449-55. doi: 10.1007/BF02249335. Psychopharmacology (Berl). 1994. PMID: 7855203 Clinical Trial.

3

On the significance of cholecystokinin receptors in panic disorder.

van Megen HJ, den Boer JA, Westenberg HG. van Megen HJ, et al. Prog Neuropsychopharmacol Biol Psychiatry. 1994 Dec;18(8):1235-46. doi: 10.1016/0278-5846(94)90090-6. Prog Neuropsychopharmacol Biol Psychiatry. 1994. PMID: 7863014 Review.

4

The panic-inducing properties of the cholecystokinin tetrapeptide CCK4 in patients with panic disorder.

van Megen HJ, Westenberg HG, Den Boer JA, Kahn RS. van Megen HJ, et al. Eur Neuropsychopharmacol. 1996 Aug;6(3):187-94. doi: 10.1016/0924-977x(96)00018-1. Eur Neuropsychopharmacol. 1996. PMID: 8880078 Clinical Trial.

5

Effect of the cholecystokinin-B receptor antagonist L-365,260 on lactate-induced panic attacks in panic disorder patients.

van Megen HJ, Westenberg HG, den Boer JA. van Megen HJ, et al. Biol Psychiatry. 1996 Oct 15;40(8):804-6. doi: 10.1016/0006-3223(96)00250-8. Biol Psychiatry. 1996. PMID: 8894076 Clinical Trial. No abstract available.

6

Cholecystokinin in anxiety.

van Megen HJ, Westenberg HG, den Boer JA, Kahn RS. van Megen HJ, et al. Eur Neuropsychopharmacol. 1996 Nov;6(4):263-80. doi: 10.1016/s0924-977x(96)00038-7. Eur Neuropsychopharmacol. 1996. PMID: 8985709 Review.

7

The cholecystokinin-B receptor antagonist CI-988 failed to affect CCK-4 induced symptoms in panic disorder patients.

van Megen HJ, Westenberg HG, den Boer JA, Slaap B, van Es-Radhakishun F, Pande AC. van Megen HJ, et al. Among authors: van es radhakishun f. Psychopharmacology (Berl). 1997 Feb;129(3):243-8. doi: 10.1007/s002130050186. Psychopharmacology (Berl). 1997. PMID: 9084062 Clinical Trial.

8

A double-blind switch study of paroxetine and venlafaxine in obsessive-compulsive disorder.

Denys D, van Megen HJ, van der Wee N, Westenberg HG. Denys D, et al. J Clin Psychiatry. 2004 Jan;65(1):37-43. doi: 10.4088/jcp.v65n0106. J Clin Psychiatry. 2004. PMID: 14744166 Clinical Trial.

9

A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors.

Denys D, de Geus F, van Megen HJ, Westenberg HG. Denys D, et al. J Clin Psychiatry. 2004 Aug;65(8):1040-8. doi: 10.4088/jcp.v65n0803. J Clin Psychiatry. 2004. PMID: 15323587 Clinical Trial.

10

Differential effects of the D1-DA receptor antagonist SCH39166 on positive and negative symptoms of schizophrenia.

Den Boer JA, van Megen HJ, Fleischhacker WW, Louwerens JW, Slaap BR, Westenberg HG, Burrows GD, Srivastava ON. Den Boer JA, et al. Among authors: van megen hj. Psychopharmacology (Berl). 1995 Oct;121(3):317-22. doi: 10.1007/BF02246069. Psychopharmacology (Berl). 1995. PMID: 8584612 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

79 results

Search Page

Filters